The EU Biotech Act – A New Era for CMC and Biopharmaceutical Manufacturing

The European Commission’s proposed EU Biotech Act (2025) represents a significant shift in how biotechnology products are developed, manufactured, and brought to market across the European Union. While much of the discussion has focused on innovation, funding, and clinical development, the Act also introduces important implications for CMC a core pillar in ensuring product quality, safety, and regulatory compliance.

This article aims to provide a CMC focused perspective on the EU Biotech Act, helping regulatory and technical professionals understand how evolving policy will shape manufacturing strategies, quality expectations, and lifecycle management approaches. As biologics, advanced therapies, and personalised medicines become more prominent, traditional CMC paradigms are increasingly under pressure to adapt to faster timelines and more complex manufacturing processes.

This article will provide actionable insights for organisations seeking to remain competitive while maintaining high standards of quality and compliance:

• A clear understanding of how the Biotech Act impacts CMC strategy and regulatory expectations
• Insight into emerging trends such as risk-based flexibility and lifecycle management
• Practical considerations for aligning CMC development with accelerated regulatory pathways

Overview of the EU Biotech Act

The EU Biotech Act, proposed in December 2025, is part of a broader regulatory and industrial strategy designed to position Europe as a global leader in biotechnology in the face of competition from markets such as USA and China. The regulation introduces a comprehensive framework covering the entire lifecycle of biotechnology products, including research, development, manufacturing, and commercialisation, focusing particularly on the area of health.

A key objective of the Act is to address structural challenges that have historically limited the EU’s ability to scale innovation into commercial success particularly in the areas of manufacturing capacity, regulatory complexity, and time-to-market. The European Commission has acknowledged that “to promote EU industrial competitiveness and its sustainability, greater efforts are needed to create the right environment for this sector to grow. European biotech and biomanufacturing companies need a supportive regulatory framework and more financing opportunities to thrive in Europe”.

Biotechnology and biomanufacturing sector in Europe, problem tree (Source: European Commission, 2025)

The key points of the proposal include measures to support innovation and competitiveness, improve access to funding and capital, and enhance biosafety, biosecurity and ethical safeguards. Amendments are proposed to the Regulation on clinical trials (CTR), the Regulation on advanced therapy medicinal products (ATMPs), the Regulation on standards of quality and safety for substances of human origin intended for human application (SoHO), the Regulation on veterinary medicinal products (VMPs) and legislation on the deliberate release of genetically modified organisms (GMO).

For CMC professionals, the Act includes measures that signal a transition from a traditionally compliance driven framework to a more integrated and strategic role within product development.

Strengthening Biomanufacturing and Supply Chain Resilience

A central pillar of the Biotech Act is the expansion of EU based biomanufacturing capabilities, aimed at reducing reliance on external regions and increasing supply chain resilience.

The Act introduces mechanisms to support recognised “strategic biotechnology projects” that strengthen EU capacity for biomanufacturing, research, innovation, skills development or priority health threat preparedness. These projects may include a cross-border element and can benefit from accelerated permitting, risk-tolerant funding, and administrative support. The highest-impact projects may include biotechnology development accelerators and centres of excellence that are intended to pool advanced equipment and expertise and lower entry barriers including for small and medium-sized enterprises, start-ups and scale-ups.

For innovative medicinal products that have undergone clinical trials and are at least partly manufactured in the EU, incentives in the form of supplementary protection certificate extensions are proposed.

From a CMC perspective, this has several implications:

• Increased emphasis on manufacturing localisation within the EU.
• Access to shared biomanufacturing infrastructure and expertise.
• Emphasis on innovative development such as platform manufacturing, analytical and digital technologies.
• Concentration of development, manufacturing, and scale-up activity within health biotechnology clusters.

Organisations may benefit from reassessing their global manufacturing footprint, particularly for pivotal and commercial production, to align with emerging policy expectations and incentives.

Shift Towards AI-enabled CMC Frameworks

Embedded throughout the Biotech Act is a recognition of advanced technologies, including artificial intelligence (AI), as enablers through the medicinal product development lifecycle. AI projects are among the strategic priorities unlocking EU funding and support. The Act aims to support trusted testing environments for AI deployment, encourage digital manufacturing, and promote AI-enabled R&D and production.

Benefits are foreseen in optimising workflows and increasing efficiency, enhancing the efficacy and safety of immunology treatments and of ATMP gene therapies and developing New Approach Methodologies (NAMs) that combine advanced experimental and computational approaches.

Regulatory Sandboxes: A Game Changer for CMC Innovation

One of the most impactful features of the Act is the extension of access to regulatory sandboxes: controlled environments where innovative products and processes can be tested under regulatory oversight. This framework allows temporary adaptations of regulatory requirements and collection of evidence to inform future approvals. It is particularly useful for ATMPs and personalised therapies, AI-enabled manufacturing systems and decentralised or patient-specific production models that do not cleanly fit within existing regulation. It is also extended to the development and testing of substances of human origin (SoHO).

CMC Relevance

Enables testing of:

• Novel product types and manufacturing technologies.
• Alternative control strategies.
• Real-world data approaches.

Accelerated Clinical and Development Timelines

The Biotech Act introduces major reforms to clinical trial processes, including:

• Reduced timelines (e.g. multinational trials from 106 to 75 days, parallel substantial modifications and removal of the additional 50-day assessment period for investigational ATMPs).
• Simplified procedures and harmonised templates.
• Introduction of “minimal-intervention” clinical trials.
• Removal of obligations for GMO risk assessments for certain low risk investigational ATMPs.

CMC Impact

• Increased need for early-stage CMC readiness.
• Greater reliance on:
  • Platform manufacturing.
  • Early process characterisation.
• Faster transition from clinical to commercial manufacturing.

Additionally, the introduction of a single core dossier for investigational products, that may be requested by the sponsor and referenced in all clinical trials related to the investigational product concerned, supports consistency in CMC documentation across multiple clinical trials and is expected to streamline the eventual time to market.

Evolution of Quality and Data Requirements for biosimilars

The Act places on a firmer legal footing its commitment to develop a tailored regulatory approach for biosimilar products, reflecting advances in manufacturing and analytical testing. The approach maintains high standards of quality and safety while reducing the requirement for clinical data.

CMC Impact

• Greater emphasis on:
  • Analytical characterisation.
  • Product comparability.
• Incentives for strategic health biotechnology projects focused on biosimilar research, development, manufacturing and marketing authorisation.

Strengthened Obligations for Biodefence and Biosecurity

The EU Biotech Act lastly establishes a framework for monitoring emerging biosecurity challenges, including systemic AI risks, and preventing the misuse of biotechnology products of concern.

Projects that support the detection, characterisation, identification, analysis and assessment of biological threats, including novel, unknown and engineered pathogens. Support for cross-border surveillance and data sharing, and development, validation of methods for the detection and attribution of genetic engineering.

Restrictions on the availability of biotechnological products of concern as identified in an annex to the Biotech Act. Introduction of a requirement to verify legitimate need when supplying such products. And the inclusion of screening mechanisms for sequences of concern generated using benchtop nucleic acid synthesis devices. Reporting of suspicious transactions.

CMC teams should be aware of screening and reporting requirements for particular biotechnology products and maintain an awareness of the Annex I list of products of biotechnological concern.

Strategic Implications for CMC Teams

The EU Biotech Act signals a broader evolution in the role of CMC within organisations. Key strategic considerations include:

• Transitioning from compliance-focused to strategy-driven CMC functions.
• Embedding regulatory flexibility and lifecycle planning early in development.
• Leveraging platform knowledge and prior experience.
• Aligning manufacturing strategies with EU policy incentives.

Companies that proactively adapt to these changes will be better positioned to accelerate development timelines while maintaining regulatory compliance. In a second stage of the EU Biotech act, following this health-focused initiative, the Commission will address in 2026 the wider biotech ecosystem beyond health to ensure a competitive internal market for all areas of biotechnology. The Commission provides the policy framework an indicative outline of possible key elements such as sectoral and horizontal enablers for example:

• Regulatory flexibility (sandboxes)
• Fast-track authorisation procedures for microbial solutions for industrial use in the bioeconomy
• Streamlined permitting for biomanufacturing projects.

Conclusion

The EU Biotech Act represents a pivotal development in the regulatory landscape, with far reaching implications for CMC. Regulatory sandboxes, accelerating development timelines, and incentivising health biotechnology projects aimed at strengthening EU manufacturing capabilities, the Act encourages a more agile and strategic approach to CMC.

At the same time, it reinforces the importance of responsible use of health biotechnology including AI, maintaining high standards of quality, safety, and compliance, ensuring that innovation does not come at the cost of patient safety. For organisations navigating these changes, the key challenge lies in balancing flexibility with control developing CMC strategies that are both efficient and robust, while aligning with evolving regulatory opportunities and expectations.

This is where regulatory expertise becomes critical. At DLRC, we support clients in adapting to complex and evolving regulatory frameworks by providing:

• Strategic guidance on CMC development and lifecycle management.
• Support in designing risk- and opportunity-based regulatory strategies.
• Expertise in IMPD, IND, and global regulatory submissions.
• Insight into EU specific regulatory requirements and policy developments.

By leveraging deep regulatory knowledge and practical experience, DLRC helps organisations navigate uncertainty, mitigate risk, and accelerate successful product development in a rapidly evolving biotech landscape.